Clinical Trial Update: A Study to Test How Well BI 1291583 is Tolerated by People With Cystic Fibrosis Bronchiectasis (Clairafly™) [Phase 2]

View source ↗

Summary

A Phase 2 study (Clairafly) assessing the tolerability of BI 1291583 in people with cystic fibrosis and bronchiectasis has completed. Results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bronchiectasis
• Cystic Fibrosis

Drugs mentioned

• BI-1291583

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Cystic Fibrosis, Bronchiectasis | Phase 2 | Status: COMPLETED | Results posted: 2025-11-18